Acceleron garners $30M in venture capital

Acceleron had rounded up $30 million in second-round venture capital to help fund drug development work. Its lead candidate is ACE-011, an experimental therapy for bone loss that is now in early-stage clinical trials. Other therapies in the pipeline include therapies for cancer, musculoskeletal and metabolic diseases. OrbiMed Advisors led the round.

- here's the report on Acceleron from the Boston Business Journal

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.